Abstract
Recombinant adeno-associated virus (rAAV) vectors have emerged as vehicles for gene therapy. In addition, anti-neoplastic properties have been attributed to wild-type AAV. To take advantage of both features and to overcome technical problems associated with rAAV preparation, we developed a production method in which rAAV particles are amplified in an infectious cycle in the presence of wtAAV. This results in a 103–104-fold amplification of rAAV input particles. rAAV-GFP particles generated by this method were used to transduce ovarian cancer cell lines to evaluate their potential in ovarian cancer gene therapy, in comparison to a rAd-GFP vector. The transduction efficiency of NIH-OVCAR3, MDAH 2774 and SKOV3 cells with rAAV-GFP particles was low (< 1%) and did not improve by increasing the number of particles/cell. Repeated administration and continued exposure of NIH-OVCAR3 and MDAH 2774 improved transduction to over 3%. In contrast, these cell lines were more efficiently transduced by rAAV-GFP in the presence of adenovirus (~15%) and by rAd-GFP (> 50%). These results indicate that in contrast to rAd vectors, rAAV particles are not suitable for therapeutic gene transfer in ovarian cancer cells unless efficient help can be provided to mediate ss to ds DNA conversion. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bantel-Schaal U (1990) Adeno-associated parvoviruses inhibit growth of cells derived from malignant human tumors. Int J Cancer 45: 190–194
Barnes MN, Deshane JS, Rosenfeld M, Siegal GP, Curiel DT and Alvarez RD (1997) Gene therapy and ovarian cancer: a review. Obstet Gynecol 89: 145–155
Batchu RB, Shammas MA, Wang JY and Munshi NC (1999) Interaction of adeno-associated virus rep78 with p53: Implications in growth inhibition. Cancer Res 59: 3592–3595
Brewis N, Phelan A, Webb J, Drew J, Elliott G and O’Hare P (2000) Evaluation of VP22 spread in tissue culture. J Virol 74: 1051–1056
Clark KR, Liu X, McGrath JP and Johnson PR (1999) Highly purified adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 10: 1031–1039
Davis LG, Dibner MD and Battey JF (1986) “Dot Blot” hybridization of labeled probe to DNA or RNA samples. In: Basic methods of molecular biology, Davis LG (ed) pp 147–149. Elsevier: New York
Ferrari FK, Samulski T, Shenk T and Samulski RJ (1996) Second strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70: 3227–3234
Fisher KJ, Gao G-P, Weitzman MD, DeMatteo R, Burda JF and Wilson JM (1996) Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis. J Virol 70: 520–532
Gao G-P, Qu G, Faust L, Engddahl RK, Xiao W, Hughes JV, Zoltick PW and Wilson JM (1998) High titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus. Hum Gene Ther 9: 2353–2361
Grimm D, Kern A, Rittner K and Kleinschmidt JA (1998) Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 9: 2745–2760
Hallek M and Wendtner C-M (1996) Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy: recent advances and potential clinical applications. Cytokines and Mol Ther 2: 69–79
He T-C, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509–2514
Hillenberg M, Schlehofer JR, von Knebel Doeberitz M and Klein-Bauernschmitt P (1999) Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2. Eur J Cancer 35: 106–110
Hoerer M, Bodegain C, Scheer U, Heberger C, Streyerer S, Burger A and Maass G (1997) The use of recombinant adeno-associated viral vector for transduction of epithelial tumor cells. Int J Immunopharmacol 19: 473–479
Khleif SN, Myers T, Carter BJ and Trempe JP (1991) Inhibition of cellular transformation by the adeno-associated virus rep gene. Virology 181: 738–741
Kube DM, Ponnazhagan S and Srivastava A (1997) Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells. J Virol 71: 7361–7371
Lui H-S, Jan M-S, Chou C-K, Chen P-H and N-J-Ke, (1999) Is green fluorescent protein toxic to the living cells. Biochem Biophys Res Commun 260: 712–717
Maass G, Bodegain C, Scheer U, Michl D, Horer M, Braun-Falco M, Volkenrandt M, Schadendorf D, Wendtner CM, Winnacker EL, Kotin RM and Hallek M (1998) Recombinant Adeno-Associated Virus for the generation of autologous, gene-modified tumor vaccines: evidence for high transduction efficiency into primary epithelial cancer cells. Hum Gene Ther 9: 1049–1059
Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, Kube DM, Yoder MC and Srivastava A (1998) Adeno-associated virus type 2 mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase and gene expression. J Virol 72: 9835–9843
Maxwell IH, Maxwell F and Schaack J (1998) An adenovirus type 5 mutant with the preterminal protein gene deleted efficiently provides helper functions for the production of recombinant adeno-associated virus. J Virol 72: 8371–8372
Peng D, Qian C, Sun Y, Barajas MA and Prieto J (2000) Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol 32: 975–985
Qing K, Wang X-S, Kube DM, Ponnazhagan S, Bajpai A and Srivastava A (1997) Role of the tyrosine phosphorylation of a cellular protein in adeno-associated virus mediated gene transfer. Proc Natl Acad Sci USA 94: 10879–10884
Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazgahan S, Zhou S, Dwarki VJ, Yoder MC and Srivavstava, (1998) Adeno-associated virus type 2 mediated gene transfer: correlation of tyrosine phophorelation of the cellular single stranded D sequence binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 72: 1593–1599
Samulski RJ, Chang LS and Shenk T (1989) Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 63: 3822–3828
Schaack J, Guo X and Langer SJ (1996) Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene. Proc Natl Acad Sci USA 93: 14686–14691
Schlehofer JR (1994) The tumor suppressive properties of adeno-associated viruses. Mutat Res 305: 303–313
Takeuchi T, Kozuka T, Nakagawa K, Aoki Y, Ohtomo K, Yoshiike K and Kanda T (2000) Adeno-associated virus type 2 nonstructural protein Rep 78 suppresses translation in vitro. Virology 266: 196–202
Tamayose K, Hirai Y and Shimada T (1996) A new strategy for large-scale preparation of high titer recombinant Adeno-Associated Virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 7: 507–513
Tenenbaum L, Hamdane M, Pouzet M, Avalosse B, Stathopoulos A, Jurysta F, Rosenbaum C, Hanemann CO, Levivier M and Velu T (1999) Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. Gene Ther 6: 1045–1053
Veldwijk MR, Schiedlmeier B, Kleinschmidt JA, Zeller WJ and Fruehauf S (1999) Superior gene transfer into solid tumor cells than into human mobilized peripheral blood progenitor cells using helpervirus free adeno-associated viral vector stocks. Eur J Cancer 35: 1136–1142
Walz C, Schlehofer JR, Flentje M, Rudat V and zur Hausen H (1992) Adeno-associated virus sensitizes HeLa cell tumors to gamma rays. J Virol 66: 5651–5657
Zolothukin S, Potter M, Hauswirth WW, Guy J and Muzyczka N (1996) A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646–4654
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Vermeij, J., Zeinoun, Z., Neyns, B. et al. Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. Br J Cancer 85, 1592–1599 (2001). https://doi.org/10.1054/bjoc.2001.2082
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2082
Keywords
This article is cited by
-
Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury
Nature Reviews Cancer (2007)
-
AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression
Gene Therapy (2004)